Compositions, methods and biomarkers for diagnostics, monitoring and therapy of various health and complex-disease conditions, such as malignant and neurodegenerative disorders, utilizing the techniques of data mining, computational biology, artificial intelligence and molecular biology are provided.

A method and a system used to determine microsatellite instability (MSI) status utilizing Next-Generation Sequencing (NGS) and a machine learning model are disclosed. The present disclosure further provides a method and a system for identifying a treatment based on the computed MSI status data for the human subject.

A method and a system used to determine microsatellite instability (MSI) status utilizing Next-Generation Sequencing (NGS) and a machine learning model are disclosed. The present disclosure further provides a method and a system for identifying a treatment based on the computed MSI status data for the human subject.

The present disclosure provides methods and systems of identifying a fibrotic disease in a subject using a DeepLearning model. The DeepLearning model may be used to predict, treat, monitor, and/or prevent the fibrotic disease in the subject, as well as to characterize a subtype of the fibrotic disease.

The present disclosure provides methods and systems of identifying a fibrotic disease in a subject using a DeepLearning model. The DeepLearning model may be used to predict, treat, monitor, and/or prevent the fibrotic disease in the subject, as well as to characterize a subtype of the fibrotic disease.

Provided herein are methods, processes and apparatuses for non-invasive assessment of genetic variations.

Provided herein are methods, processes and apparatuses for non-invasive assessment of genetic variations.

The present disclosure provides compositions and methods for the generation of an antibody or immunogenic composition, such as a vaccine, through epitope focusing by variable effective antigen surface concentration. Generally, the composition and methods of the disclosure comprise three steps: a “design process” comprising one or more in silico bioinformatics steps to select and generate a library of potential antigens for use in the immunogenic composition; a “formulation process”, comprising in vitro testing of potential antigens, using various biochemical assays, and further combining two or more antigens to generate one or more immunogenic compositions; and an “administering” step, whereby the immunogenic composition is administered to a host animal, immune cell, subject or patient. Further steps may also be included, such as the isolation and production of antibodies raised by host immune response to the immunogenic composition.

Disclosed herein are methods for the direct readout of proteoforms and complexes thereof, such as immunoglobulins. The method may comprise ionizing a sample with an ionizer, wherein the sample comprises a mixture of different proteoforms or complexes thereof; detecting a multiplicity of ions generated by the ionization of the sample with a current detector; determining ion masses for each of the multiplicity of ions detected with the current detector with a mass analyzer; generating a mass-domain spectrum from the ion masses with the mass analyzer. The method may also comprise determining one or more metrics capturing the heterogeneity or relative abundance of proteoforms.

Techniques for generating therapy biomarker scores and visualizing same. The techniques include determining, using a patient's sequence data and distributions of biomarker values across one or more reference populations, a first set of normalized scores for a first set of biomarkers associated with a first therapy, and a second set of normalized scores for a second set of biomarkers associated with a second therapy, generating a graphical user interface (GUI) including a first portion associated with the first therapy and having at least one visual characteristic determined based on a normalized score of the respective biomarker in the first set of normalized scores; and a second portion associated with a second therapy and having at least one visual characteristic determined based on a normalized score of the respective biomarker in the second set of normalized scores; and displaying the generated GUI.